One trial, one purpose or many stakeholder perspectives?
At the same time, the phrase itself is deceptively simple. According to the Cambridge Dictionary, fit for purpose means:
“Suitable and good enough to do what it is intended to do.”
Fit for Purpose in ICH GCP (R3)
Within ICH GCP E6(R3), fit for purpose is used to describe a wide range of elements, including trial processes, quality management systems, oversight mechanisms, data handling approaches, and supporting technologies. Across all these contexts, the underlying principle is consistent: systems and processes should be appropriate for their intended use, proportionate to risk, and focused on what truly matters for participant safety and reliable decision-making.
Importantly, GCP does not define quality as maximal data collection or maximal procedural complexity. Instead, quality is framed as appropriateness, doing what is necessary to achieve reliable, ethical outcomes, while avoiding unnecessary burden and inefficiency.
This interpretation aligns closely with Quality by Design and risk-based approaches, which emphasize early identification of critical factors and intentional design rather than retrospective control.
A Single Trial in a Much Larger Evidence Landscape
A single clinical trial is only one fragment of a much larger drug development and evidence-generation lifecycle. That lifecycle typically spans pre-clinical research, early clinical phases, confirmatory trials, post-marketing commitments, and increasingly, Real World Evidence (RWE).
From a regulatory perspective, the purpose of an individual trial may be relatively narrow: demonstrating safety and efficacy for a specific indication, population, and endpoint. From a broader perspective, however, clinical trials also serve:
-
Scientific understanding of disease and mechanisms
-
Long-term benefit–risk evaluation
-
Comparative effectiveness and healthcare decision-making
-
Patient-relevant insights beyond primary endpoints
In this sense, fit for purpose can mean different things depending on the level at which “purpose” is defined. A trial may be perfectly fit for its immediate regulatory objective, while still being insufficient to fully support broader scientific, healthcare, or patient-oriented questions.
Evidence Generation and the Limits of Data Minimization
Quality by Design and risk-based methodologies place strong emphasis on identifying critical-to-quality data and minimizing unnecessary collection. This focus is well justified: excessive data collection increases participant burden, site workload, monitoring complexity, and long-term governance costs.
At the same time, science presents an uncomfortable reality: it is often impossible to know in advance which data will ultimately prove important.
In exploratory and hypothesis-generating research, data are not collected solely to confirm predefined assumptions, but also to identify patterns, relationships, and signals that may only become visible after analysis. From this perspective, strict predefinition of “critical data” inevitably reflects existing knowledge and expectations. It can introduce a form of epistemic bias, directing attention toward what is already known and potentially limiting sensitivity to unexpected findings.
This does not mean that unlimited data collection is desirable or defensible. Over-collection can dilute signal with noise, complicate interpretation, and create downstream obligations that outweigh any theoretical benefit. The challenge, therefore, is not choosing between minimal and maximal data, but being explicit about why data are collected and how they are intended to be used.
An Open Topic Worth Discussing
This leads to an open and constructive discussion point for the industry: should “fit for purpose” be understood as a single principle, or as a multi-layered concept reflecting different purposes of evidence generation?
One possible way forward is to distinguish between:
-
Confirmatory data, directly supporting primary objectives and participant safety
-
Interpretive data, needed to contextualize and understand trial results
-
Exploratory data, intended to inform future hypotheses, program-level decisions, or linkage with RWE
In such a framework, fit for purpose does not automatically imply deleting or avoiding data. Instead, it implies intentionality: each data element is linked to a defined purpose, with appropriate levels of control, governance, and justification. Data that lack a clear purpose are out of scope by design, while exploratory data are collected transparently, with explicit limitations and expectations.
This approach aligns with the spirit of GCP, Quality by Design, and evolving evidence strategies, without reducing scientific inquiry to the narrowest possible interpretation of trial objectives.
Conclusion
“Fit for purpose” in ICH GCP is not a mandate to collect as little data as possible. It is a mandate to understand purpose clearly, design accordingly, and remain proportionate. A single clinical trial may be fit for its immediate regulatory goal, yet still incomplete as a contribution to science, healthcare, and patient understanding.
Acknowledging this tension does not weaken Quality by Design. On the contrary, it may represent the next step in aligning regulatory rigor with the realities of evidence generation across the full lifecycle of drug development.
This is how data integrity is described in Good Clinical Practice document:
"Data integrity includes the degree to which data fulfill key criteria of being attributable, legible, contemporaneous, original, accurate, complete, secure and reliable such that data are fit for purpose."
No comments:
Post a Comment